CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers

A gynecologic oncology group study

Chunqiao Tian, Maurie Markman, Richard Zaino, Robert F. Ozols, William P. McGuire, Franco M. Muggia, Peter G. Rose, David Spriggs, Deborah Kay Armstrong

Research output: Contribution to journalArticle

Abstract

BACKGROUND: There are limited data regarding unique clinical or laboratory features associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers (EOC), particularly the relationship between CA-125 antigen levels and prognosis. METHODS: A retrospective review of 7 previously reported Gynecologic Oncology Group phase 3 trials in patients with stage III/IV EOC was conducted. A variety of clinical parameters were examined, including the impact of baseline and changes in the CA-125 level after treatment of CC and MU EOC on progression-free (PFS) and overall survival (OS). RESULTS: Clinical outcomes among patients with advanced CC and MU EOC were significantly worse when compared with other cell types (median PFS, 9.7 vs 7.0 vs 16.7 months, respectively, P

Original languageEnglish (US)
Pages (from-to)1395-1403
Number of pages9
JournalCancer
Volume115
Issue number7
DOIs
StatePublished - Apr 1 2009

Fingerprint

Drug Therapy
CA-125 Antigen
Survival
Ovarian epithelial cancer
Therapeutics

Keywords

  • CA-125
  • Clear cell cancer
  • Mucinous cell cancer
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers : A gynecologic oncology group study. / Tian, Chunqiao; Markman, Maurie; Zaino, Richard; Ozols, Robert F.; McGuire, William P.; Muggia, Franco M.; Rose, Peter G.; Spriggs, David; Armstrong, Deborah Kay.

In: Cancer, Vol. 115, No. 7, 01.04.2009, p. 1395-1403.

Research output: Contribution to journalArticle

Tian, Chunqiao ; Markman, Maurie ; Zaino, Richard ; Ozols, Robert F. ; McGuire, William P. ; Muggia, Franco M. ; Rose, Peter G. ; Spriggs, David ; Armstrong, Deborah Kay. / CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers : A gynecologic oncology group study. In: Cancer. 2009 ; Vol. 115, No. 7. pp. 1395-1403.
@article{2f8e5a455762472fa496920a513fb02f,
title = "CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: A gynecologic oncology group study",
abstract = "BACKGROUND: There are limited data regarding unique clinical or laboratory features associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers (EOC), particularly the relationship between CA-125 antigen levels and prognosis. METHODS: A retrospective review of 7 previously reported Gynecologic Oncology Group phase 3 trials in patients with stage III/IV EOC was conducted. A variety of clinical parameters were examined, including the impact of baseline and changes in the CA-125 level after treatment of CC and MU EOC on progression-free (PFS) and overall survival (OS). RESULTS: Clinical outcomes among patients with advanced CC and MU EOC were significantly worse when compared with other cell types (median PFS, 9.7 vs 7.0 vs 16.7 months, respectively, P",
keywords = "CA-125, Clear cell cancer, Mucinous cell cancer, Ovarian cancer",
author = "Chunqiao Tian and Maurie Markman and Richard Zaino and Ozols, {Robert F.} and McGuire, {William P.} and Muggia, {Franco M.} and Rose, {Peter G.} and David Spriggs and Armstrong, {Deborah Kay}",
year = "2009",
month = "4",
day = "1",
doi = "10.1002/cncr.24152",
language = "English (US)",
volume = "115",
pages = "1395--1403",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers

T2 - A gynecologic oncology group study

AU - Tian, Chunqiao

AU - Markman, Maurie

AU - Zaino, Richard

AU - Ozols, Robert F.

AU - McGuire, William P.

AU - Muggia, Franco M.

AU - Rose, Peter G.

AU - Spriggs, David

AU - Armstrong, Deborah Kay

PY - 2009/4/1

Y1 - 2009/4/1

N2 - BACKGROUND: There are limited data regarding unique clinical or laboratory features associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers (EOC), particularly the relationship between CA-125 antigen levels and prognosis. METHODS: A retrospective review of 7 previously reported Gynecologic Oncology Group phase 3 trials in patients with stage III/IV EOC was conducted. A variety of clinical parameters were examined, including the impact of baseline and changes in the CA-125 level after treatment of CC and MU EOC on progression-free (PFS) and overall survival (OS). RESULTS: Clinical outcomes among patients with advanced CC and MU EOC were significantly worse when compared with other cell types (median PFS, 9.7 vs 7.0 vs 16.7 months, respectively, P

AB - BACKGROUND: There are limited data regarding unique clinical or laboratory features associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers (EOC), particularly the relationship between CA-125 antigen levels and prognosis. METHODS: A retrospective review of 7 previously reported Gynecologic Oncology Group phase 3 trials in patients with stage III/IV EOC was conducted. A variety of clinical parameters were examined, including the impact of baseline and changes in the CA-125 level after treatment of CC and MU EOC on progression-free (PFS) and overall survival (OS). RESULTS: Clinical outcomes among patients with advanced CC and MU EOC were significantly worse when compared with other cell types (median PFS, 9.7 vs 7.0 vs 16.7 months, respectively, P

KW - CA-125

KW - Clear cell cancer

KW - Mucinous cell cancer

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=63449109983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449109983&partnerID=8YFLogxK

U2 - 10.1002/cncr.24152

DO - 10.1002/cncr.24152

M3 - Article

VL - 115

SP - 1395

EP - 1403

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -